Physician profile
Vito Daniel Palumbo
NPI 1700841756
$4,125.04
in general payments reported to CMS, 2019-2025
35 companies · $776 in 2025
The $776 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,189 · 2020: $146 · 2022: $1,033 · 2023: $554 · 2024: $428 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $624.39 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.86 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Abbvie INC. | $345.89 | 2019-2024 | |
| Pfizer INC. | $296.01 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $207.20 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $203.93 | 2019-2023 | |
| Novo Nordisk INC | $190.28 | 2019-2025 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $189.89 | 2019-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.42 | 2024-2025 | Xifaxan |
| Amgen INC. | $142.75 | 2019-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $141.84 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $130.65 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $126.49 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $102.70 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Gilead Sciences, INC. | $93.76 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $80.72 | 2019-2025 | Freestyle Libre 3 |
| Seqirus USA INC | $79.31 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Daiichi Sankyo INC. | $75.75 | 2019 | |
| Edwards Lifesciences Corporation | $75.60 | 2023-2025 | Sapien 3 Ultra Resilia |
| Ars Pharmaceuticals Operations, INC. | $54.73 | 2025 | Neffy |
| Bayer Healthcare Pharmaceuticals INC. | $46.11 | 2022-2023 | |
| Axsome Therapeutics, INC. | $41.37 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $41.32 | 2023-2024 | Voquezna |
| Boston Scientific Corporation | $31.24 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $28.99 | 2023 | Prehevbrio |
| Kowa Pharmaceuticals America, INC. | $27.98 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.69 | 2022 | |
| Allergan, INC. | $17.56 | 2019 | |
| Genentech USA, INC. | $16.25 | 2019 | |
| Kaleo, INC. | $16.18 | 2022 | |
| Grifols USA, LLC | $14.09 | 2019 | |
| Verona Pharma, INC. | $14.03 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $13.95 | 2019 | |
| Dexcom, INC. | $12.88 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vito Palumbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.